Introduction: Gay, bisexual and queer (GBQ) men are at disproportionately higher risk of acquiring HIV and other sexually transmitted infections (STI). While HIV/STI testing rates among GBQ men are increasing worldwide, they remain suboptimal in a variety of settings.
Methods And Analysis: The study is a pragmatic randomised controlled trial designed to evaluate an online video series developed by a community-based organisation in Singapore for GBQ men. A total of 300 HIV-negative GBQ men in Singapore aged 18-29 years old will be recruited for this study. Participants will subsequently be randomised into the intervention arm (n=150) and the control arm (n=150). The intervention arm (n=150) will be assigned the intervention along with sexual health information via a pamphlet, while the control group (n=150) will be assigned only the sexual health information via a pamphlet. Participants should also not have watched the video prior to their participation in this study, which will be ascertained through a questionnaire. Primary outcomes for this evaluation are changes in self-reported intention to test for, actual testing for and regularity of testing for HIV, syphilis, chlamydia and gonorrhoea at the 3 and 6 months after intervention. Secondary outcomes include changes in self-reported risk perception for HIV and other STIs, knowledge of HIV, knowledge of risks associated with acquiring STIs, knowledge of HIV pre-exposure prophylaxis, consistent condom use for anal sex with casual partners, incidence of STIs, connectedness to the lesbian, gay, bisexual and transgender community, self-concealment of sexual orientation, perceived homophobia, internalised homophobia, HIV testing self-efficacy and HIV testing social norms.
Ethics And Dissemination: The study has been approved by the National University of Singapore Institutional Review Board (S-19-059) and registered at ClinicalTrials.gov. The results will be published in peer-reviewed academic journals and disseminated to community-based organisations and policymakers.
Trial Registration Number: NCT04021953.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170638 | PMC |
http://dx.doi.org/10.1136/bmjopen-2019-033855 | DOI Listing |
Asia Ocean J Nucl Med Biol
January 2025
Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.
Background: Anabolic androgenic steroids (AAS) are synthetic forms of testosterone frequently used as performance enhancing drugs among gay, bisexual, and queer (GBQ) men. Despite widespread use, associated harms, and the likely existence of an AAS use disorder, there is no medical consensus on standards of care for people who use AAS, with most medical providers focusing exclusively on abstinence. Individuals using AAS have developed community-based harm reduction strategies to mitigate these harms.
View Article and Find Full Text PDFPsychol Trauma
September 2024
Department of Psychology, Hiatt School of Psychology, Clark University.
Objective: The Pulse Nightclub shooting is the deadliest act of violence against the lesbian, gay, bisexual, transgender, and queer community in U.S.
History: After the shooting, communities came together to process the violence and grieve the victims.
Curr Oncol
September 2024
Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy.
The aim of the present study was to evaluate the safety and efficacy of radionuclide therapy with [Lu]Lu-DOTA-TATE according to our single center experience at the University of Naples Federico II. For the present analysis, we considered 21 patients with progressive, advanced, well-differentiated G1 and G2 in patients with gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs) treated with [Lu]Lu-DOTA-TATE according to the decisions of a multidisciplinary team. All patients underwent four cycles of 7-8 GBq of [Lu]Lu-DOTA-TATE every 8 weeks.
View Article and Find Full Text PDFJ Nucl Med
June 2024
Department of Nuclear Medicine, University Hospital Essen, Essen, Germany;
Prospective results have demonstrated favorable safety and efficacy of [Lu]Lu-PSMA radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant prostate cancer. However, no systematic data are available outlining the feasibility of extended therapy beyond 6 cycles. We aim to evaluate the safety and efficacy of extended [Lu]Lu-PSMA radiopharmaceutical therapy in patients who have received more than 6 cycles.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!